日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Everyday Heroes

Playing hardball, negotiator secures nation's health

By Wang Xiaoyu | CHINA DAILY | Updated: 2021-06-23 09:10
Share
Share - WeChat

Few bargaining videos can have garnered as much attention and praise as the one featuring Xu Wei, head of the Zhejiang Provincial Medical Insurance Bureau's Medical Services Management Department.

In the clip from November 2019, Xu, who leads a team of medical insurance experts, managed to cut the price of dapagliflozin tablets from 5.62 yuan ($0.87) to 4.36 yuan per tablet during negotiations with pharmaceutical company representatives.

Dapagliflozin tablets are used to treat Type 2 diabetes, which affects about 11 percent of Chinese population. The medication's average price on the international market is about 7 to 8 yuan.

The meeting in late 2019 was part of a national initiative aimed at lowering drug prices and alleviating the public's medical burden.

Since 2018, the National Healthcare Insurance Administration has conducted four rounds of negotiations with drug companies, and has centralized procurement campaigns.

A total of 533 drugs have been selected so far and their prices have fallen by an average of 53 percent, the administration said recently, as it gears up for the latest round of negotiations, which are set to begin in the second half of this year.

Some of Xu's comments in the video went viral, prompting netizens to coin a new term-"soul bargaining tactics"-to describe his bold, assertive approach.

When one representative said that the price they were offering was already lower than in South Korea, Xu replied: "Have you ever thought about the huge population in China? We are negotiating with you with the entire country behind us. You have one more opportunity to get this right."

In response to a new quote of 4.4 yuan, Xu said, "There are too many fours. Four sounds bad in Chinese. How about taking off another 0.04 yuan down? Is 4.36 yuan OK?"

It was not until the representative nodded that Xu's pokerface broke into a slight smile. "We hope you will keep making good drugs, and keep making our people healthy," he said.

When asked why he pressed so hard for a decrease of as little as 0.01 yuan, Xu said that "there are more than 100 million diabetes patients in China. Suppose 10 percent use dapagliflozin tablets, a small reduction of 0.01 yuan could save 100,000 yuan per day, and 36 million yuan annually. So even an extremely small reduction should not be overlooked."

In addition to the direct benefit to patients, Xu said price negotiations can bring many more positive outcomes, including maintaining the balance of the country's medical insurance funds, helping drugmakers tap into the domestic market, and providing a wider range of products for hospitals to choose from.

He said that during negotiations, he often stressed that as long as pharmaceutical companies offer the best price, their interests will be protected. "In the face of disease, we are not adversaries, but allies," he said.

As the latest version of the national reimbursement drug list took effect on March 1, the Administration said that it estimated patients will save about 28 billion yuan this year, thanks to the reductions.

"With price cuts to 14 anti-cancer drugs, cancer patients alone are projected to save more than 3 billion yuan," said Xiong Xianjun, head of the administration's Medical Services Supervision Department.

On June 17, the General Office of the State Council released a circular laying out 20 key tasks in deepening healthcare reform this year. One is to expand the use of drugs selected during price negotiation campaigns, and improve relevant policies by the end of August.

In addition, the administration is closely monitoring the clinical outcomes of generic drugs that have been added to the national bulk-buying program, in order to address the concerns of some patients.

In a report released by the administration on June 9, it said that a two-year study into 14 generic drugs selected during the first round of negotiations shows that they match name-brand counterparts in terms of safety and efficacy.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 欧美在线观看视频 | 国产精品毛片久久久久久 | 国产欧美日韩在线观看 | 久久久精品视频免费看 | 奇米第四狠狠777高清秒播 | 爱视频福利| 午夜影院在线免费观看视频 | 久久免费视频一区二区三区 | 免费久久一级欧美特大黄 | 国产精品毛片一区二区在线看 | 午夜丰满少妇高清毛片1000部 | 亚洲精品午夜电影 | 亚洲国产精品综合久久网络 | 亚洲码欧美码一区二区三区 | 日韩成人中文字幕 | 国产在线小视频 | 色婷婷.com| 91免费大片 | 日韩在线免费观看视频 | 手机成人免费视频 | 久久精品国产99国产精品 | 亚洲天堂2013 | 欧美日韩一区二区三区在线观看 | 久操中文 | 欧美最爽乱淫视频免 | 91麻豆蜜桃一区二区三区 | 中日欧洲精品视频在线 | 香蕉视频日本 | 国产在线欧美精品中文一区 | av免费在线观看网站 | 性夜黄a爽影免费看 | 黄视频免费在线观看 | 波多野结衣一区二区三区88 | 中国免费毛片 | 91看片免费在线观看 | 久草最新视频 | 日日摸夜夜添夜夜添亚洲女人 | 午夜手机电影 | 国产一区不卡 | 日韩不卡一区二区 | 一级@片|